Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1

• Zachary D. Wallen
• Mary K. Nesline
• Marni Tierno
• Alison Roos
• Erica Schnettler
• Hatim Husain
• Pratheesh Sathyan
• Brian Caveney
• Marcia Eisenberg
• 1 more
• Shakti H. Ramkissoon